KURA
Kura Oncology, Inc.
Healthcare · Biotechnology · NMS
$10.24
Close 2026-05-28
✓ ETHICAL PASS

UNKNOWN MOAT
HIGH
Data Confidence: 86%
Full financial profile available
Market Cap
$909.0M
Trailing P/E
Forward P/E
-4.01
Rev Growth
+29.5%
Profit Margin
0.0%
ROE
-124.7%
Analyst Target
$28.00
Recommendation
STRONG BUY
About Kura Oncology, Inc.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Ethical Screen
Business ActivityPASS
Debt RatioN/A
Cash RatioN/A
Receivables RatioN/A
Revenue Ratio (0.00%)PASS
OverallPASS
Score Ethical: 64.7
Score Valuation: 33.0
Score Quality: 33.8
Score Combined: 37.8

Full Analysis

Opportunity scores, earnings history, insider transactions, institutional holders, analyst consensus, and more.

Unlock with Membership
Opportunity Scores
Valuation50.0
Quality25.0
Cash Flow0.0
Moat40.0
Balance Sheet0.0
Debt Purity50.0
Liquid Purity50.0
Rev Purity100.0
Compliance100.0
Tier: WATCH · Score: 37.4 · Rank: #4553
Insider Transactions
No insider transaction data.
Top Institutional Holders
No institutional holder data.
Additional Fundamentals
Enterprise Value
$328.5M
Price/Book
8.21
Beta
0.316
Analysts
12
Total Revenue (TTM)
$71.6M
Total Debt
$24.3M
Rec. Mean
1.27
Short Ratio
11.69
Short % Float
0.2%
Employees
260

Elite Intelligence

Trade Consideration with position sizing, convergence signals, and risk analysis. Available to Elite members.

Upgrade to Elite
Trade Consideration
The Opportunity
Score 37.8 (P39 — top 60.9% of scored tickers). Unknown Moat. Ethical PASS. 12 analysts at Strong Buy.
Price: $10.24 | Target: $31.17 (+204%)
Score
38
Moat
Unknown
Conviction
Standard
Upside
+204%
The Fundamentals
Revenue Growth+29.5%
Profit Margin0.0%
ROE-124.7%
Forward P/E-4.0
Market Cap$909.0M
Position Sizing Scenarios
Stop: $8.70 (-15%) | Entry: $10.24
SharesCostProfit to TargetR:R
To Consensus ($31.17, 12 analysts)
10$102.40+$209.30 (204%)13.6R
50$512.00+$1,046.50 (204%)13.6R
100$1,024.00+$2,093.00 (204%)13.6R
Risk Factors
  • Elevated short interest (11.69 days to cover)
The Verdict
Kura Oncology, Inc. passes all ethical screens, holds a unknown competitive moat, and is growing revenue at +29.5%.
Quantitative Grade

A single score combining all analytical layers below. A is strongest, D is weakest.

B
Quant Score
59.1
Risk Grade
Layers
7
Risk Profile

How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.

VaR 95%
-5.2%
worst expected daily loss, 19 in 20 days
CVaR 95%
-8.6%
avg loss on the worst 5% of days
Annual Volatility
Sortino Ratio
-0.68
above 1.0 is good
Max Drawdown
-76.2%
Worst Day
Forward Outlook

Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.

30d Prob Up
90d Prob Up
Median Return 30d
Liquidity Score
65
Liquidity Grade
LIQUID
Trend & Momentum

What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?

Kalman Trend
Trend Strength
Momentum Signal
HMM Regime
RSI Signal
Technical Signals

Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.

MA Crossover
DEATH_CROSS
Bollinger Position
UPPER_HALF
Beta
Relative Volume
0.8x
Short Interest
Financial Health

Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.

Altman Z-Score
below 1.81 = distress zone
Piotroski F-Score
Earnings Beat Rate
Earnings Consistency
Correlations

These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.

Most Correlated
TickerCorrelation
XNCR0.460
IMNM0.443
ARKG0.436
CLDX0.434
NRIX0.431
Inverse Correlated
TickerCorrelation
PRFX-0.178
BAES.L-0.160
AMC.AX-0.159
5218.KL-0.125
BJ-0.124
Seasonality

Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.

Best Day
Monday
Worst Day
Tuesday
Best Month
Aug
Worst Month
Dec
Fri-Mon Effect
-0.9784493835323471
Momentum Rankings

How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.

1M Return
+12.9%
3M Return
+15.3%
6M Return
-15.0%
12M Return
+77.7%
Momentum Rank
#1167
Momentum Signal
UP

Get our daily market read free. Join thousands of traders.

Free Explorer Access